- Home
- ECOR vs MRSN Comparison
ECOR vs MRSN Comparison
Compare ECOR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- MRSN
- Stock Information
- Founded
- ECOR 2005
- MRSN 2001
- Country
- ECOR United States
- MRSN United States
- Employees
- ECOR 62
- MRSN N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ECOR Health Care
- MRSN Health Care
- Exchange
- ECOR Nasdaq
- MRSN Nasdaq
- Market Cap
- ECOR 39.6M
- MRSN 47.1M
- IPO Year
- ECOR 2018
- MRSN 2017
- Fundamental
- Price
- ECOR $4.74
- MRSN $8.46
- Analyst Decision
- ECOR Strong Buy
- MRSN Strong Buy
- Analyst Count
- ECOR 2
- MRSN 3
- Target Price
- ECOR $25.50
- MRSN $33.00
- AVG Volume (30 Days)
- ECOR 39.5K
- MRSN 59.5K
- Earning Date
- ECOR 11-05-2025
- MRSN 11-13-2025
- Dividend Yield
- ECOR N/A
- MRSN N/A
- EPS Growth
- ECOR N/A
- MRSN N/A
- EPS
- ECOR N/A
- MRSN N/A
- Revenue
- ECOR $27,700,000.00
- MRSN $34,769,000.00
- Revenue This Year
- ECOR $24.55
- MRSN N/A
- Revenue Next Year
- ECOR $41.13
- MRSN N/A
- P/E Ratio
- ECOR N/A
- MRSN N/A
- Revenue Growth
- ECOR 30.16
- MRSN 16.14
- 52 Week Low
- ECOR $4.16
- MRSN $5.21
- 52 Week High
- ECOR $19.49
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- ECOR 42.03
- MRSN 43.65
- Support Level
- ECOR $4.88
- MRSN $8.00
- Resistance Level
- ECOR $5.17
- MRSN $9.87
- Average True Range (ATR)
- ECOR 0.24
- MRSN 0.66
- MACD
- ECOR -0.00
- MRSN -0.28
- Stochastic Oscillator
- ECOR 35.06
- MRSN 16.64
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.